
Veru (VERU) Stock Forecast & Price Target
Veru (VERU) Analyst Ratings
Bulls say
Veru Inc. is positioned well within the expanding biopharmaceutical market, particularly given the promising outcomes from recent GLP-1 clinical trials, which may lead to an accelerated growth trajectory for similar therapies due to their beneficial impacts on weight loss and reduced health risks. The significant market opportunity in muscle preservation and obesity treatment is underscored by the explosive growth of competitors' revenue, exemplified by Zepbound's sales increasing from $2.3 billion in 1Q25 to $3.6 billion in 3Q25, indicating strong market demand and potential for Veru's offerings. Furthermore, the dramatic rise in global spending on obesity medications, from approximately $3 billion in 2020 to over $30 billion by 2024, reflects a substantial and growing market that Veru could tap into with its innovative drug development programs.
Bears say
Veru Inc. faces significant risks related to the potential failure of its development programs, which can severely hamstring future revenue growth and lead to a decline in stock value. The company is also navigating intense competition that may pressure revenue expectations and escalate regulatory hurdles impacting drug approval chances. Additionally, high turnover in key regulatory roles such as CEO and CMO raises concerns about the company's strategic stability and could further negatively impact share performance.
This aggregate rating is based on analysts' research of Veru and is not a guaranteed prediction by Public.com or investment advice.
Veru (VERU) Analyst Forecast & Price Prediction
Start investing in Veru (VERU)
Order type
Buy in
Order amount
Est. shares
0 shares